|
US10626372B1
(en)
|
2015-01-26 |
2020-04-21 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
EP3310932B1
(en)
|
2015-06-17 |
2023-08-30 |
The UAB Research Foundation |
Crispr/cas9 complex for genomic editing
|
|
US11555207B2
(en)
|
2015-06-17 |
2023-01-17 |
The Uab Research Foundation |
CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
|
ES2768984T3
(es)
|
2015-10-05 |
2020-06-24 |
Prec Biosciences Inc |
Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
|
|
ES2803728T3
(es)
|
2015-10-05 |
2021-01-29 |
Prec Biosciences Inc |
Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
|
|
US12642852B1
(en)
*
|
2015-11-04 |
2026-06-02 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
CN122146606A
(zh)
|
2015-11-04 |
2026-06-05 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
|
AU2017248259A1
(en)
*
|
2016-04-07 |
2018-10-25 |
Bluebird Bio, Inc. |
Chimeric antigen receptor T cell compositions
|
|
KR102614675B1
(ko)
|
2016-04-15 |
2023-12-19 |
메모리얼 슬로안 케터링 캔서 센터 |
유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
|
|
IL264439B2
(en)
*
|
2016-08-17 |
2024-08-01 |
Factor Bioscience Inc |
non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
|
|
IL265953B2
(en)
*
|
2016-10-19 |
2026-05-01 |
Cellectis Sa |
Gene insertion designed to target for enhanced immune cell therapy
|
|
EP3532075A4
(en)
*
|
2016-10-27 |
2020-07-08 |
Intima Bioscience, Inc. |
VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS
|
|
EP3606550A2
(en)
|
2017-04-03 |
2020-02-12 |
Neon Therapeutics, Inc. |
Protein antigens and uses thereof
|
|
IL270361B2
(en)
|
2017-05-01 |
2025-04-01 |
Univ Pennsylvania |
Monoclonal antibodies against alpha-synuclein fibrils
|
|
MY200418A
(en)
|
2017-06-15 |
2023-12-25 |
Univ California |
Targeted non-viral dna insertions
|
|
EP4775669A2
(en)
|
2017-06-30 |
2026-07-15 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
EP3658578A1
(en)
*
|
2017-07-26 |
2020-06-03 |
Cellectis |
Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection
|
|
BR112020005938A2
(pt)
*
|
2017-09-27 |
2020-11-17 |
University Of Southern California |
célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
|
|
SG11202003798TA
(en)
|
2017-10-27 |
2020-05-28 |
Univ California |
Targeted replacement of endogenous t cell receptors
|
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
|
SG11202007622SA
(en)
*
|
2018-02-11 |
2020-09-29 |
Memorial Sloan Kettering Cancer Center |
Non-hla restricted t cell receptors and uses thereof
|
|
CA3090793C
(en)
*
|
2018-02-16 |
2024-10-08 |
Kite Pharma, Inc. |
MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE
|
|
US20200224160A1
(en)
*
|
2018-02-27 |
2020-07-16 |
Sorrento Therapeutics, Inc. |
Process for dna integration using rna-guided endonucleases
|
|
EP3781176A4
(en)
*
|
2018-04-09 |
2022-05-25 |
The Trustees of the University of Pennsylvania |
METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
|
|
KR102617818B1
(ko)
|
2018-04-12 |
2023-12-27 |
프리시젼 바이오사이언시스 인코포레이티드 |
인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
|
|
US20210113617A1
(en)
*
|
2018-04-17 |
2021-04-22 |
Wake Forest University Health Sciences |
Methods and compositions for th9 cell mediated cancer treatment
|
|
US20210207174A1
(en)
*
|
2018-05-25 |
2021-07-08 |
The Regents Of The University Of California |
Genetic engineering of endogenous proteins
|
|
CN112533942A
(zh)
|
2018-06-01 |
2021-03-19 |
华盛顿大学 |
嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制
|
|
SG11202012653XA
(en)
|
2018-06-19 |
2021-01-28 |
Biontech Us Inc |
Neoantigens and uses thereof
|
|
CN110616188B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种通用型car-t细胞及其制备方法和应用
|
|
US12359169B2
(en)
|
2018-06-20 |
2025-07-15 |
Shanghai Longyao Biotechnology Inc., Ltd. |
Universal CAR-T cell and preparation method and use thereof
|
|
WO2020010110A1
(en)
*
|
2018-07-03 |
2020-01-09 |
Unum Therapeutics Inc. |
Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
|
|
WO2020022512A1
(ja)
*
|
2018-07-26 |
2020-01-30 |
国立大学法人京都大学 |
外来抗原レセプター遺伝子導入細胞の製造方法
|
|
WO2020037066A1
(en)
|
2018-08-14 |
2020-02-20 |
Unum Therapeutics Inc. |
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
|
|
CA3116132A1
(en)
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
EP4578507A3
(en)
|
2018-11-01 |
2025-11-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
US20220000921A1
(en)
*
|
2018-11-20 |
2022-01-06 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Modified Cell Expressing Therapeutic Agent and Uses thereof
|
|
KR20250116790A
(ko)
|
2018-12-12 |
2025-08-01 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
CN113286875B
(zh)
*
|
2018-12-19 |
2024-08-09 |
Inserm(法国国家健康医学研究院) |
表达嵌合抗原受体的黏膜相关不变t(mait)细胞
|
|
JP7642548B2
(ja)
*
|
2019-02-01 |
2025-03-10 |
ケーエスキュー セラピューティクス， インコーポレイテッド |
免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
|
|
US12419913B2
(en)
|
2019-02-08 |
2025-09-23 |
Dna Twopointo, Inc. |
Modification of CAR-T cells
|
|
CA3130489A1
(en)
*
|
2019-02-18 |
2020-08-27 |
Memorial Sloan-Kettering Cancer Center |
Combinations of multiple chimeric antigen receptors for immunotherapy
|
|
AU2020232789B2
(en)
*
|
2019-03-06 |
2026-04-09 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
|
CN113661173B
(zh)
|
2019-03-29 |
2024-10-01 |
豪夫迈·罗氏有限公司 |
通过以限定的组织形式靶向整合多个表达盒来产生表达FcRn的细胞的方法
|
|
CN113906133A
(zh)
*
|
2019-04-11 |
2022-01-07 |
菲特治疗公司 |
工程改造的iPSC和免疫效应细胞中的CD3重建
|
|
SG11202111372VA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
EP3969482A1
(en)
*
|
2019-05-16 |
2022-03-23 |
University of Washington |
Lockr-mediated recruitment of car t cells
|
|
KR20220024637A
(ko)
*
|
2019-06-19 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법
|
|
EP3999079A4
(en)
|
2019-07-19 |
2024-04-03 |
Memorial Sloan Kettering Cancer Center |
Fusion polypeptide for immunotherapy
|
|
EP4003407A1
(en)
|
2019-07-23 |
2022-06-01 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
CN117925528A
(zh)
*
|
2019-07-24 |
2024-04-26 |
浙江煦顼技术有限公司 |
具有增强记忆t细胞表型的修饰t细胞
|
|
CN115175987A
(zh)
*
|
2019-09-23 |
2022-10-11 |
明尼苏达大学董事会 |
基因编辑的免疫细胞和治疗方法
|
|
WO2021061946A2
(en)
|
2019-09-25 |
2021-04-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
A promoter specific for non-pigmented ciliary epithelial cells
|
|
SG10201909544YA
(en)
*
|
2019-10-11 |
2021-05-28 |
Nat Univ Singapore |
Genetically Modified T Cells And Uses Thereof
|
|
AU2020382219A1
(en)
|
2019-11-13 |
2022-05-12 |
Crispr Therapeutics Ag |
Manufacturing process for making T cells expressing chimeric antigen receptors
|
|
WO2021095012A1
(en)
*
|
2019-11-13 |
2021-05-20 |
Crispr Therapeutics Ag |
Methods of manufacturing car-t cells
|
|
CN113122576A
(zh)
*
|
2019-12-31 |
2021-07-16 |
博雅辑因（北京）生物科技有限公司 |
一种通用型truck-t细胞、其制备方法以及用途
|
|
WO2021137241A1
(en)
*
|
2020-01-02 |
2021-07-08 |
Edity Therapeutics Ltd. |
Delivery compositions and methods
|
|
EP4110356A4
(en)
*
|
2020-02-28 |
2024-03-27 |
Wisconsin Alumni Research Foundation |
NON-VIRAL GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS OBTAINED BY GENE EDITING
|
|
US20240245805A1
(en)
*
|
2020-03-20 |
2024-07-25 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
JP7809068B2
(ja)
|
2020-04-24 |
2026-01-30 |
メモリアル スローン ケタリング キャンサー センター |
Ｃｄ１９を標的とするキメラ抗原受容体およびその使用
|
|
GB202006903D0
(en)
*
|
2020-05-11 |
2020-06-24 |
Adaptimmune Ltd |
Modified iPSCs
|
|
JP2023532347A
(ja)
*
|
2020-06-29 |
2023-07-27 |
セル メディカ，インコーポレイテッド |
キメラ抗原受容体の緊張性シグナル伝達を減少させる方法および組成物
|
|
WO2022011065A1
(en)
*
|
2020-07-07 |
2022-01-13 |
The Nemours Foundation |
Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer
|
|
JP7886313B2
(ja)
|
2020-07-30 |
2026-07-07 |
アンスティテュ・クリー |
Ｓｏｃｓ１に欠陥のある免疫細胞
|
|
AU2021320556A1
(en)
*
|
2020-08-07 |
2023-03-09 |
Neogene Therapeutics B.V. |
Methods to enrich genetically engineered T cells
|
|
JP2023544337A
(ja)
*
|
2020-09-30 |
2023-10-23 |
ブイオーアール バイオファーマ インコーポレーテッド |
キメラ抗原受容体発現系
|
|
EP4236969A4
(en)
*
|
2020-10-29 |
2024-12-11 |
Arsenal Biosciences, Inc. |
COMPOSITIONS AND METHODS FOR GENOMIC MODIFICATION OF CELLS AND USES THEREOF
|
|
WO2022118310A1
(en)
*
|
2020-12-01 |
2022-06-09 |
Lepton Pharmaceuticals Ltd. |
Methods for enhancing therapeutic efficacy of isolated cells for cell therapy
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
EP4019538A1
(en)
*
|
2020-12-22 |
2022-06-29 |
Charité - Universitätsmedizin Berlin |
Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes
|
|
IL305804A
(en)
|
2021-03-11 |
2023-11-01 |
Inst Curie |
Transmembrane neoantigenic peptides
|
|
US20250352577A1
(en)
|
2021-03-11 |
2025-11-20 |
Mnemo Therapeutics |
Tumor neoantigenic peptides and uses thereof
|
|
CA3212964A1
(en)
|
2021-03-11 |
2022-09-15 |
Mnemo Therapeutics |
Tumor neoantigenic peptides
|
|
WO2022241232A1
(en)
*
|
2021-05-14 |
2022-11-17 |
Appia Bio, Inc. |
Production of engineered t cells from stem cells
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
US20230124097A1
(en)
*
|
2021-10-14 |
2023-04-20 |
Appia Bio, Inc. |
Engineering stem cell t cells with multiple t cell receptors
|
|
US20250000907A1
(en)
*
|
2021-11-22 |
2025-01-02 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Engineered immune cells with reduced sirt6 expression
|
|
JP2025501272A
(ja)
|
2021-12-28 |
2025-01-17 |
ムネモ・セラピューティクス |
不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
|
|
CN115304679B
(zh)
*
|
2022-01-21 |
2024-07-16 |
郑州大学第一附属医院 |
一种促进t细胞分化的限制型car及其应用
|
|
AU2023209589A1
(en)
|
2022-01-21 |
2024-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Modulation of suv39h1 expression by rnas
|
|
US20250170242A1
(en)
*
|
2022-03-17 |
2025-05-29 |
University Of Florida Research Foundation, Incorporated |
Chimeric lactate receptor engineered t cells
|
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
|
WO2023225670A2
(en)
*
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
EP4573114A4
(en)
|
2022-08-19 |
2026-07-29 |
Memorial Sloan Kettering Cancer Center |
T-LYMPHOCYTE RECEPTORS TARGETTING RAS MUTATIONS AND ASSOCIATED USES
|
|
EP4580604A4
(en)
*
|
2022-09-02 |
2026-08-12 |
Oncosenx Inc |
COMPOSITIONS AND IN VIVO EXPRESSION METHODS OF CHIMERIC ANTIGENIC RECEPTORS
|
|
BE1031219B1
(fr)
|
2022-12-28 |
2024-07-29 |
Quidditas Sa |
Composition, cellules immunitaires la comprenant et utilisation de ces dernières
|
|
KR20260105764A
(ko)
*
|
2023-10-30 |
2026-07-07 |
알로젠 테라퓨틱스 인코포레이티드 |
조작된 세포
|
|
WO2025096594A2
(en)
*
|
2023-10-30 |
2025-05-08 |
Allogene Therapeutics, Inc. |
Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025213167A1
(en)
*
|
2024-04-05 |
2025-10-09 |
Roswell Park Cancer Institute Corporation |
Complement signaling as a t-cell checkpoint in the tumor microenvironment (tme)
|
|
WO2025259702A1
(en)
*
|
2024-06-10 |
2025-12-18 |
Adoptracell, Inc. |
Method for generating car-t cells in which car expression is coupled with expression of endogenous foxp3, and compositions and methods of use thereof
|
|
WO2026062222A1
(en)
|
2024-09-20 |
2026-03-26 |
Institut Curie |
Novel protein isoforms and uses
|